PE
NTLA icon

Point72 Europe’s Intellia Therapeutics NTLA Stock Holding History

Point72 Europe’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$228K Buy
+13,210
New +$163K 0.01% 184

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Europe's NTLA Position: Q3 2025 in Review

Point72 Europe opened a new position in Intellia Therapeutics (NTLA) in Q3 2025: 13,210 shares worth $228K. The stake represents 0.01% of the portfolio and ranks #184 among its holdings.

282 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

  • Point72 Europe held 13,210 shares of Intellia Therapeutics worth $228K as of Q3 2025.
  • Intellia Therapeutics was a new Point72 Europe position in Q3 2025.
  • Intellia Therapeutics made up 0.01% of Point72 Europe's portfolio in Q3 2025, its #184 holding.
  • 282 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.